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ABSTRACT
Background & Aims: It is important to determine the magnitude and identify
modifiers of the rate of response to placebo in clinical trials of fistulizing Crohn’s
disease (CD), to understand disease progression and calculate sample size. We
conducted a systematic review and meta-analysis of rates of response to placebo in
trials of patients with fistulizing CD.
Methods: We searched MEDLINE, EMBASE, EMBASE CLASSIC, and the
Cochrane central register of controlled trials for randomized controlled trials (RCTs)
comparing pharmacologic agents with placebo in adults with fistulizing CD. We
identified studies that reported complete fistula closure, partial closure or response.
Data were extracted as intention-to-treat analyses, and pooled using a random effects
model. Proportions of patients who received placebo and had complete or partial
fistula(e) closure were calculated, with 95% confidence intervals (CIs). The effects of
trial characteristics on the magnitude of response to placebo were examined.
Results: Thirteen RCTs were eligible for our analysis; these included 579 patients
assigned to placebo groups. The pooled rate of response to placebo, among all RCTs,
for complete fistula closure was 15.6% (95% CI, 10.9%−20.9%), with significant 
heterogeneity (I2 = 62.5%; P=.001). The pooled rate of response to placebo for partial
fistula closure or response in 9 trials, comprising 423 patients, was 18.3% (95% CI,
14.8%–22.1%). Rates of response to placebo were significantly lower in trials with
shorter durations of therapy and shorter intervals to assessment of fistula closure.
Neither exposure to the pharmacologic agent during the induction phase of the same
(or a related) RCT, nor concomitant medications, had any effect.
Conclusions: In a meta-analysis of rate of response to placebo in patients with
fistulizing CD, we found that fistulas closed in almost 1/6 patients given placebo in
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RCTs of pharmacologic agents. Future research should identify characteristics of
patients that predict response to placebo.
KEY WORDS: IBD; fistula; meta-analysis; randomized controlled trials; placebo
effect
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INTRODUCTION
Perianal fistulizing disease affects up to 40% of patients with Crohn’s disease
(CD) . 1 It reflects an aggressive disease behavior, leading to irreversible structural
damage, and has been shown to be an independent predictor for a disabling course of
disease. 2 If perianal fistulizing disease is associated with abscess formation combined
surgical and medical management is recommended, but if not then conservative
medical approaches only, including treatment with antibiotics, immunosuppressants,
and/or tumor necrosis factor α-inhibitors are appropriate. 3
Evidence from the systematic review literature suggests that a significant
proportion of patients assigned to placebo will respond to therapy, even in RCTs of
therapies for organic GI conditions such as inflammatory bowel disease or peptic
ulcer, where mucosal or ulcer healing are often the outcomes of interest. 4, 5 Placebo
response rates in luminal CD have been the subject of prior systematic analysis. 6-9
Endpoints such as the Crohn’s disease activity index, 10 are weighted towards patient
reported outcome measures, which may drive the high placebo response and
remission rates sometimes observed. The adoption of more objective measures of
disease activity in trial endpoints in more recent years, including inflammatory
biomarkers, radiological imaging, or mucosal healing may minimize this.
Clinical trials in fistulizing CD almost exclusively recruit patients with fistulae
draining to the body surface, predominantly the skin. The majority of these fistulae
are located in the perianal region. The endpoints in trials of fistulizing CD appear to
be more objective and range from partial response, usually defined by a 50% or more
reduction in the number of draining fistulae, up to fistula closure referring to complete
cessation of drainage. 11 Despite the fact that there have been several published RCTs
of pharmacological therapies in fistulizing CD, the magnitude of the placebo response
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rate has not been studied. This is important, since high placebo response rates will
statistically reduce the possibility of detecting a positive impact of active therapy, and
RCTs should be designed to minimize placebo response. We have therefore
conducted a systematic review and meta-analysis in order to assess the magnitude of
the placebo response rate in treatment trials of fistulizing CD, and have examined trial
characteristics and features of design that may influence this.
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METHODS
Search Strategy and Trial Selection
A search of the medical literature was conducted using EMBASE CLASSIC
and EMBASE (1947 to February 2014), and MEDLINE (1948 to February 2014) and
the Cochrane central register of controlled trials (2014). Randomized controlled trials
examining the effect of pharmacological therapies in adult patients (over the age of 18
years) with fistulizing CD were eligible for inclusion (Box 1). The first period of
cross-over RCTs were also eligible for inclusion. In the case of all RCTs the control
arm were required to receive placebo. Time point of fistula assessment had to be at
least 4 weeks after therapy commenced, and RCTs had to report complete fistula
closure, or partial fistula closure or fistula response.
Placebo-controlled trials in CD were identified with the terms Crohn disease,
inflammatory bowel disease, colitis, or ileitis (both as medical subject headings and
free text terms), and Crohn$ disease or regional enteritis (as free text terms). These
were combined using the set operator AND with studies identified with the free text
term fistul$. There were no language restrictions and abstracts of the papers identified
by the initial search were evaluated by the lead reviewer for appropriateness to the
study question, and all potentially relevant papers were obtained and evaluated in
detail. Foreign language papers were translated where necessary. Abstract books of
conference proceedings from the Digestive Diseases Week, European Crohn’s and
Colitis Organization, and United European Gastroenterology Week between 2001 and
2013 were hand-searched to identify potentially eligible RCTs published only in
abstract form. The bibliographies of all identified eligible trials were used to perform
a recursive search of the literature. Articles were independently assessed by two
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reviewers using pre-designed eligibility forms, according to the prospectively defined
eligibility criteria (Box 1). Any disagreement between investigators was resolved by
consensus.
Outcome Assessment
The primary outcome assessed was the magnitude of the placebo response rate,
in terms of complete fistula closure, or partial fistula closure or fistula response, at
study end in all RCTs of pharmacological therapies conducted in fistulizing CD.
Secondary outcomes included assessment of placebo response rate according to
different trial characteristics.
Data Extraction
All data were extracted independently by two reviewers on to a Microsoft
Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) as
dichotomous outcomes (complete fistula closure, or partial fistula closure or fistula
response, in the placebo arms of the included RCTs). In addition, the following
clinical data were extracted for each trial: geographical location, number of centers,
dosing schedule of the placebo, route of administration, duration of therapy, time
point at which fistula closure was assessed, whether patients were exposed to open-
label active therapy during an earlier induction phase of the same, or a related, RCT,
the proportion of trial patients receiving placebo, active pharmacological therapy used,
primary outcome measure used to define complete fistula closure, or partial fistula
closure or fistula response, and whether it was patient versus physician-reported,
location of the fistula(e), and proportion of individuals taking concomitant
medications for CD at trial entry. Data were extracted as intention-to-treat analyses,
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with all drop-outs assumed to be treatment failures, wherever trial reporting allowed
this.
Assessment of Risk of Bias
Risk of bias assessment was performed independently by two investigators,
with disagreements resolved by discussion. Risk of bias was assessed as described in
the Cochrane handbook, 12 by recording the method used to generate the
randomization schedule and conceal allocation, whether blinding was implemented
for participants, personnel and outcome assessment, what proportion of subjects
completed follow-up, and whether there was evidence of selective reporting of
outcomes.
Data Synthesis and Statistical Analysis
Data were pooled using a random effects model, to give a more conservative
estimate of the magnitude of the placebo response rate, allowing for any heterogeneity
between trials. 13 Outcomes were expressed as the pooled proportion of patients
assigned to placebo with complete fistula closure, or partial fistula closure or fistula
response, after completion of therapy, with a 95% confidence interval (CI).
The results of individual RCTs can be diverse, and this inconsistency within a
single meta-analysis can be quantified with a statistical test of heterogeneity, to assess
whether the variation across trials is due to true heterogeneity, or chance. This
quantity is termed I2, and its value ranges from 0% to 100%, with 0% representing no
observed heterogeneity, and larger values indicating increasing heterogeneity. A value
below 50% was chosen to represent low levels of heterogeneity. 14
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Subgroup analyses were conducted for rates of complete fistula closure,
according to route of administration of the placebo, duration of therapy, time point at
which fistula closure was assessed, whether patients were exposed to active therapy
during an earlier induction phase of the same, or a related, RCT, proportion of
individuals taking concomitant medications at trial entry including 5-aminosalicylates,
glucocorticosteroids, immunosuppressants, or antibiotics, and active pharmacological
therapy used. We did not performed meta-regression in this systematic review and
meta-analysis, but rather subgroup analyses according to individual trial
characteristics, because the former technique evaluates the average of patient
characteristics within each trial, and this summary data may misrepresent individual
patients within each treatment arm. The technique is therefore vulnerable to giving
spurious results due to the ecological fallacy. 15
StatsDirect version 2.7.2 (StatsDirect Ltd, Sale, Cheshire, England) was used
to generate Forest plots of the pooled proportions of patients assigned to placebo with
complete fistula closure, or partial fistula closure or fistula response, after completion
of therapy, with 95% CIs. Pooled placebo response rates were compared between the
pre-defined subgroups using the Cochran Q statistic in order to assess for any
heterogeneity between placebo response rates for the different subgroup analyses we
conducted and, due to multiple analyses, a P value of < 0.01 was considered
statistically significant.
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RESULTS
The search strategy generated 9063 citations of which 44 appeared to be
relevant to the systematic review and were retrieved for further assessment (Figure 1).
Of these 44 RCTs, 31 were excluded for the reasons listed, leaving 13 eligible trials,
16-28 containing 579 individuals with fistulizing CD who were randomized to receive
placebo. Agreement between reviewers for assessment of trial eligibility was good
(kappa statistic = 0.90). Characteristics of individual RCTs, including the magnitude
of the placebo response in each trial, are provided in Table 1. Three trials included
only patients with perianal fistulizing disease with fistula closure as the primary
endpoint, 17, 18, 28 three trials recruited patients with fistulizing disease exclusively, but
at any location, 20, 22, 26 again reporting fistula closure as the primary endpoint, and
seven trials reported fistula closure as a secondary endpoint within a mixed population
of patients with either luminal or fistulizing CD. 16, 19, 21, 23-25, 27 Six trials were at low
risk of bias. 18, 19, 21, 22, 24, 25 Definitions of fistula closure and fistula response used in
each trial are provided in Table 2.
Placebo Response Rates for Complete Fistula Closure and Partial Fistula
Closure or Response in All Trials
The pooled placebo response rate for complete fistula closure in the 13 RCTs
that we identified, and judged by the investigator in all studies, was 15.6% (95% CI
10.9% to 20.9%). There was considerable heterogeneity between trials (I2 = 62.5%, P
= 0.001). The placebo response rate in individual RCTs varied from 5.9% to 43.3%
(Figure 2). There were nine trials that reported partial fistula closure or response. 17-22,
24, 26, 28 The pooled placebo response rate in these trials was 18.3% (95% CI 14.8% to
22.1%), with no significant heterogeneity between studies (I2 = 0.4%, P = 0.43)
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(Figure 3). Seven trials used closure of ≥50% of fistulas to define response, 17, 20-22, 24,
26, 28 with the other two trials using improvement or partial closure, 19 or a decrease in
the perianal Crohn’s disease activity index of ≥5 (Table 2). 18 When only those seven
RCTs that used the same definition of partial fistula closure or response were included
in the analysis, the pooled placebo response rate was 18.6% (95% CI 14.5% to 23.1%),
again with no significant heterogeneity between studies (I2 = 9.8%, P = 0.35).
Placebo Response Rate for Complete Fistula Closure According to Fistula
Location, Route of Administration of Placebo Duration of Therapy, and Time
Point at which Fistula Closure was Assessed
Pooled placebo response rates were generally lower among studies that
recruited exclusively those with perianal disease compared with those that included
patients with fistulae at any location (10.1% vs. 18.1%), with a trend towards this
difference being statistically significant (Cochran Q = 4.32, P = 0.04). Pooled placebo
response rate for complete fistula closure was lowest in the one trial that used a
topical route of administration (7.3%), 18 and highest in the four trials that used
subcutaneous administration (23.3%) (Table 3). Heterogeneity between studies was
confined to those using a subcutaneous route, with no heterogeneity detected when
only the four trials that used the oral route or the four trials that used intravenous
administration were included. Differences in pooled placebo response rates did not
reach formal statistical significance, although there was a trend towards a lower rate
with oral administration compared with either intravenous or subcutaneous (Cochran
Q = 4.55, P = 0.03 and Cochran Q = 4.49, P = 0.03 respectively). Duration of therapy
varied from 2 to 56 weeks. Pooled placebo response rate in trials using >10 weeks of
therapy was 21.2%, which was significantly higher than in RCTs that used ≤10 weeks 
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of therapy (10.3%, Cochran Q = 7.53, P = 0.006) (Table 3). Time point at which
fistula closure was assessed ranged from 4 to 56 weeks, with pooled response rates
again significantly higher in trials with >10 weeks of follow-up, compared with those
with ≤10 weeks (20.3% vs. 9.9%, Cochran Q = 6.52, P = 0.01) (Table 3).  
Placebo Response Rate for Complete Fistula Closure According to Exposure to
Active Therapy During Induction, Concomitant Medication at Trial Entry, and
Active Therapy
There were four trials in which patients were exposed to active therapy during
induction therapy before being re-randomized to placebo. 16, 25-27 Placebo response
rates were higher in these four trials, but this difference was not statistically
significant (20.6% vs. 13.2%, Cochran Q = 3.16, P = 0.075) (Table 3). There were
seven RCTs that reported the proportion of placebo patients receiving concomitant
therapy at trial entry with 5-ASAs, glucocorticosteroids, or immunosuppressants, 16-18,
20, 22, 26, 28 and six that reported use of concomitant antibiotics. 17, 18, 20, 22, 26, 28 We used
a threshold of ≥30% of the placebo arm using these drugs to distinguish between 
individual trials for all of these analyses. There were no significant differences
observed between placebo response rates according to use of 5-ASAs,
glucocorticosteroids, immunosuppressants, or antibiotics, although the placebo
response rates in trials where ≥30% of the placebo arm were using glucorticosteroids 
were generally higher (16.8% vs. 10.0%, Cochran Q = 3.87, P = 0.05) (Table 3).
Biological drugs were the active pharmacological agent used in the greatest
number of trials. 16, 20, 21, 23-27 Generally, placebo response rates appeared higher in
these trials, but this was not significantly greater than in trials using antibiotics,
immunosuppressants, or AST-120 carbon microspheres (Cochran Q = 2.24, P = 0.13,
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Cochran Q = 2.35, P = 0.13, and Cochran Q = 4.82, P = 0.03 respectively). Among
individual biologics used, pooled placebo response rates were higher in the two trials
that used certolizumab (35.8%) compared with trials using other drugs, where placebo
response rates varied between 11.1% and 18.1% (Table 3).
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DISCUSSION
This systematic review and meta-analysis of placebo-controlled randomized
trials conducted in patients with fistulizing CD has demonstrated a pooled placebo
response rate of 15.6% for complete fistula closure in 13 studies, and 18.3% for
partial fistula closure or fistula response in nine trials. Pooled placebo response rate
was significantly higher in trials using >10 weeks of therapy, and trials in which
fistula closure was assessed at >10 weeks, compared with those ≤10 weeks. There was 
also a trend towards a lower placebo response rate in patients with perianal fistula,
and with oral, compared with either intravenous or subcutaneous, administration.
Active therapy used, whether there was exposure to this during an induction phase of
the same, or a related, RCT and concomitant medication use at trial entry did not
appear to affect placebo response rates, although rates were generally higher in RCTs
where patients were exposed to active therapy during induction, and in trials where
≥30% of those assigned to placebo were using concomitant glucocorticosteroids.  
Strengths of the present study include the search strategy, which was
exhaustive, in order to maximize the number of identified RCTs providing data for
these analyses. We assessed the impact of individual trial characteristics on pooled
placebo response rates in subgroup analyses. We also performed an intention-to-treat
analysis, where all drop-outs were assumed to be treatment failures, and used a
random effects model to provide a more conservative estimate of the pooled placebo
response rate, meaning that the magnitude of this effect is unlikely to have been
overestimated.
Weaknesses of the study include the fact that there was statistically significant
heterogeneity when trial data were pooled in our primary analysis, although this
appeared to resolve in some of our subgroup analyses, including route of
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administration, duration of therapy, and time point at which fistula closure was
assessed. In addition, cessation of drainage from fistulae (‘closure’) does not equate to
healing, since MRI scanning will generally show persistent fistulous tracks even when
drainage ceases. 29 It can also be argued that RCTs examine medical therapy to the
exclusion of surgical management, although in clinical practice combined medical and
surgical management, particularly seton insertion, 30 is the standard of care. 3 Despite
the detailed analyses we conducted, it is important to point out that, without access to
individual patient level data, it is difficult to draw any firm conclusions about specific
patient characteristics that may predict a response to placebo in patients with
fistulizing CD. Finally, although we conducted a subgroup including only trials that
recruited patients with perianal fistulizing CD exclusively, we were not able to assess
the effect of exact fistula location on placebo response rate.
There have been several published systematic reviews and meta-analyses that
have examined the placebo response rates in luminal CD. 6-9 In the most definitive of
these, which examined placebo response rates in active CD across all therapies, the
pooled placebo response rate was 18%, similar to that we observed. The other three
meta-analyses restricted themselves to specific therapies, or situations such as post-
operative recurrence of CD. However, none have studied this issue specifically in
fistulizing CD. The results of this study are therefore novel and important, as they can
be used to inform the design of future studies testing novel or existing therapies in
fistulizing CD.
Given that most of the outcomes reported in the trials we identified were
investigator-reported, and therefore objective rather than subjective, it is unlikely that
the magnitude of the placebo response has been exaggerated in this meta-analysis.
Possible explanations for the finding that placebo response rates were significantly
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higher in RCTs with longer duration of therapy, and a longer time to assessment of
fistula closure, are speculative but it may be that, as treatment or follow-up continues
in fistulizing CD, there is more likely to be closure with placebo due to regression to
the mean, hence the results of our meta-analysis provide an approximation of the
spontaneous closure rate of fistulizing CD. This theory is supported by a previous
meta-analysis of placebo response rates in luminal CD, where increasing duration of
follow-up was significantly associated with higher placebo response rates. 6
Whether the closure rates of fistulae in these trials is a true effect of placebo,
or due to a combination of concomitant medications, other standardized best care, or
spontaneous healing is difficult to judge. The concept of placebo as an active
treatment with beneficial effects on mind and body has been reported by other
investigators in the field of functional GI disorders. 31 With this in mind, it is
interesting to note that closure rates with placebo were generally higher in trials that
used a non-oral route of administration, which suggests that preconceived conscious
or subconscious expectations of the efficacy of the assigned treatment, as judged by
the patient, may impact on the likelihood of response to a placebo. 32
The fact that we did not observe any significant differences in placebo
response rates according to whether patients were exposed to active therapy at an
earlier stage of the trial, or concomitant medication use, is perhaps surprising, but in
the former case there were only four studies of biologic agents where patients
received open-label drug therapy prior to re-randomization and pooled rates of fistula
closure with placebo were generally higher in these trials, and in the latter instance not
all trials reported these data, meaning that our meta-analysis may have been
underpowered to detect any difference in closure rates according to these patient
characteristics. This underlines the need for access to patient level data when
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examining the exact impact of these aspects of trial design or patient characteristics on
outcome measures with any great accuracy. This would also allow the impact of
baseline disease activity or inflammatory markers on rates of fistula closure or
response with placebo to be studied, something we were unable to examine in our
meta-analysis. This issue was examined in one of the included RCTs, 28 and it
appeared that patients with lower clinical and inflammatory activity were more likely
to experience closure of fistulae with placebo.
The number of patients with fistulizing CD experiencing complete fistula
closure with placebo in this study appears to be somewhere between one in five and
one in 10. When partial fistula closure or response to therapy was assessed, this was
between one in five and one in seven. This information is important for the conduct of
future RCTs in fistulizing CD, as it may be helpful in informing power calculations on
which to base trial recruitment. To date, only one drug that has been studied
exclusively in a population of patients with fistulizing CD is licensed for use, 20, 26
underlining the fact that there is still a huge unmet need for the development and
testing of novel therapies for this disabling and difficult to treat condition. Our study
results should help in designing future trials of drugs with variable mechanisms of
action.
This systematic review and meta-analysis has demonstrated a pooled fistula
closure rate of 15.6% in all available RCTs of pharmacological therapies, and a partial
fistula closure or fistula response rate of 18.3%. This highlights that partial response
rates lead to higher estimates of efficacy, and that more stringent endpoints should be
preferred in subsequent trials of therapies in fistulizing CD, in order to minimize
placebo response rates and maximize the likelihood of detecting a beneficial effect of
active therapy over placebo. Future research should concentrate on identifying patient
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characteristics that predict such a response to treatment, ideally using trial data at the
individual patient level.
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Box 1. Eligibility criteria.
Randomized controlled trials.
Adults (participants aged > 18 years) with active fistulizing Crohn’s disease.
Compared pharmacological therapies with placebo.
Contained >15 patients in the placebo arm.
Time point of fistula assessment had to be at least 4 weeks after therapy commenced.
Assessment of complete or partial fistula closure following therapy.
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TABLES
Table 1. Characteristics of Included Trials.
Trial Geographical
location
Active treatment* Duration of
therapy
Point at
which
fistula
closure
assessed
Sample size (%
perianal)
Placebo response
rate for complete
fistula closure
(%)
Placebo response
rate for partial
fistula closure or
response (%)
Fistula endpoint
primary or
secondary analysis
Present 1980
19
USA , one
center
Mercaptopurine
1.5m/kg o.d orally
52 weeks 52 weeks 46
(not reported)
1/17 (5.9) 4/17 (23.5) Secondary
Present 1999
20
Multinational,
12 centers
Infliximab 5mg or
10mg/kg at weeks
0, 2, and 6
intravenously
6 weeks 18 weeks 94
(90%)
4/31 (12.9) 8/31 (25.8) Primary
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Sandborn
2003 22
USA and
Canada, 18
centers
Tacrolimus
0.1mg/kg b.i.d
orally
10 weeks 10 weeks 48
(91%)
2/26 (7.7) 2/26 (7.7) Primary
Sandborn
2004 21
Multinational,
68 centers
CDP571 10mg/kg
every 8 weeks
intravenously
24 weeks 28 weeks 86
(not reported)
5/26 (19.2) 5/26 (19.2) Secondary
Sands 2004 26 Multinational,
45 centers
Infliximab 5mg/kg
every 8 weeks
intravenously
46 weeks 54 weeks 195
(90%)
19/99 (19.2) 23/99 (23.2) Primary
Sandborn
2007a 24
Multinational,
52 centers
Adalimumab
160mg at week 0
and 80mg at week 2
subcutaneously
2 weeks 4 weeks 45
(not reported)
2/25 (8.0) 5/25 (20.0) Secondary
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Sandborn
2007b 23
Multinational,
171 centers
Certolizumab
400mg at weeks 0,
2, and 4 and then
every 4 weeks
subcutaneously
24 weeks 26 weeks 107
(not reported)
19/61 (31.1) Not reported Secondary
Schreiber
2007 27
Multinational,
147 centers
Certolizumab
400mg every 4
weeks
subcutaneously
24 weeks 26 weeks 58
(not reported)
13/30 (43.3) Not reported Secondary
Fukuda 2008
17
Japan, 19
centers
AST-120 2g t.i.d
orally
8 weeks 8 weeks 62 (100%) 2/31 (6.5) 3/31 (9.7) Primary
Colombel
2009 16
Multinational,
92 centers
Adalimumab 40mg
weekly or every
other week
subcutaneously
56 weeks 56 weeks 117
(97%)
6/47 (12.8) Not reported Secondary
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Maeda 2010 18 UK and USA,
12 centers
Metronidazole 10%
ointment t.i.d
topically
4 weeks 4 weeks 74
(100%)
3/41 (7.3) 5/41 (12.2) Primary
Sandborn
2013 25
Multinational,
285 centers
Vedolizumab
300mg at week 0
and 2 then every 4
or 8 weeks
intravenously
52 weeks 52 weeks 57
(not reported)
2/18 (11.1) Not reported Secondary
Reinisch 2014
28
Multinational,
289 centers
AST-120 2g t.i.d
orally
8 weeks 8 weeks 249
(100%)
14/127 (11.0) 21/127 (16.5) Primary
*o.d. once daily, b.i.d. twice daily, t.i.d. three times daily
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Table 2. Fistula Location, Definition of Fistula Closure and Fistula Response Used in Each Trial.
Trial Fistula location Definition of fistula closure Definition of partial fistula closure or response
Present 1980 19 Any Complete closure Improvement or partial healing
Present 1999 20 Any Absence of any draining fistulae at two consecutive visits Reduction of ≥50% of draining fistulae at two consecutive 
visits
Sandborn 2003
22
Any Closure of all open, draining fistulae and maintenance of
closure for ≥4 weeks 
Closure of ≥50% of open, draining fistulae and maintenance of 
closure for ≥4 weeks 
Sandborn 2004
21
Any Closure of 100% of fistulae on two consecutive visits over a 6-
week period
Closure of ≥50% of fistulae on two consecutive visits over a 6-
week period
Sands 2004 26 Any Absence of draining fistulae Reduction of ≥50% of draining fistulae at two consecutive 
visits ≥4 weeks apart 
Sandborn
2007a 23
Any Closure of all draining fistulae at both of weeks 2 and 4 Reduction of ≥50% of draining fistulae at both of weeks 2 and 
4
Sandborn
2007b 24
Any Absence of any draining fistulae at two consecutive visits Not reported
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Schreiber 2007
27
Any Absence of any draining fistulae at two consecutive visits ≥3 
weeks apart
Not reported
Fukuda 2008 17 Perianal only Closure of all draining fistulae at both of weeks 4 and 8 Closure of ≥50% of fistulae at both of weeks 4 and 8 
Colombel 2009
16
Any Absence of any draining fistulae Not reported
Maeda 2010 18 Perianal only No discharge from fistulae Decrease in the perianal Crohn’s disease activity index of ≥5 
Sandborn 2013
25
Any Closure of draining fistulae Not reported
Reinisch 2014 28 Perianal only Closure of all draining fistulae at both of weeks 4 and 8 50% reduction in the number of draining fistulae at both of
weeks 4 and 8
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Table 3. Effect of Trial Characteristics on Magnitude of the Placebo Response for Complete Fistula Closure.
Number of
trials
Number of patients
receiving placebo
Pooled placebo
response rate for
complete fistula
closure (%)
95%
confidence
interval
I2 (%) P value for I2
All trials 13 579 15.6 10.9 – 20.9 62.5 0.001
Fistula location
Perianal only
Any
3
10
199
380
10.1
18.1
6.3 – 14.6
12.2 – 24.8
0
59.9
0.75
0.008
Route of administration of placebo
Topical
Oral
Intravenous
Subcutaneous
1
4
4
4
41
201
174
163
7.3
10.1
17.8
23.3
1.5 – 19.9
6.4 – 14.6
12.6 – 23.8
10.6 – 39.2
N/A*
0
0
79.6
N/A*
0.91
0.81
0.002
Duration of therapy
≤10 weeks 
> 10 weeks
6
7
281
298
10.3
21.2
7.1 – 14.1
13.8 – 29.8
0
63.2
0.96
0.01
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Time point at which fistula closure
assessed
≤10 weeks 
> 10 weeks
5
9
250
329
9.9
20.3
6.6 – 13.9
13.7 – 27.9
0
59.9
0.96
0.015
Placebo patients exposed to active
therapy during induction
Yes
No
4
9
194
385
20.6
13.2
15.2 – 26.4
8.4 – 18.9
70.9
53.4
0.02
0.03
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Concomitant medication use at trial
entry in placebo arm
<30% 5-ASAs
≥30% 5-ASAs 
<30% glucocorticosteroids
≥30% glucocorticosteroids 
<30% immunosuppressants
≥30% immunosuppressants 
<30% antibiotics
≥30% antibiotics 
1
6
4
3
2
5
4
2
47
324
225
177
62
340
298
57
12.8
12.7
10.0
16.8
10.7
13.1
12.4
11.7
4.8 – 25.7
9.0 – 16.6
6.4 – 14.2
11.7 – 22.6
4.4 – 19.3
9.3 – 17.4
7.6 – 18.1
4.8 – 21.0
N/A*
14.2
0
0
N/A*
17.7
44.7
N/A*
N/A*
0.32
0.89
0.58
N/A*
0.30
0.14
N/A*
Ford et al. 36 of 37
Active pharmacological therapy
Antibiotic
Immunosuppressant
AST-120
Biological therapy
CDP571
Vedolizumab
Adalimumab
Certolizumab
Infliximab
1
2
2
8
1
1
2
2
2
41
43
158
337
26
18
91
72
130
7.3
8.7
10.6
20.3
19.2
11.1
12.1
35.8
18.1
1.5 – 19.9
2.4 – 18.6
6.3 – 15.8
13.7 – 27.8
6.6 – 39.4
1.4 – 34.7
5.7 – 20.4
25.0 – 47.5
12.0 – 25.1
N/A*
N/A*
N/A*
60.4%
N/A*
N/A*
N/A*
N/A*
N/A*
N/A*
N/A*
N/A*
0.014
N/A*
N/A*
N/A*
N/A*
N/A*
*N/A: not applicable, too few studies to assess for heterogeneity
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FIGURES
Figure 1. Flow Diagram of Assessment of Trials Identified in the Systematic
Review.
Figure 2. Forest Plot of Pooled Placebo Response Rates for Complete Fistula
Closure.
Figure 3. Forest Plot of Pooled Placebo Response Rates for Partial Fistula
Closure or Response.
